Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Jorge Dimartino"'
Autor:
Anand Patel, Laura Michaelis, Gary Schiller, Ronan Swords, Lawrence E. Morris, Luis A. Carvajal, Gordon Bray, Elizabeth A. Olek, Richard Cutler, Jorge Dimartino, Eytan Stein
Publikováno v:
HemaSphere, Vol 7, p e1492994 (2023)
Externí odkaz:
https://doaj.org/article/0fcdebe12f7f4ca5b2f0a3bf48e1eb43
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Mean paclitaxel plasma concentrations following nab-paclitaxel administration alone or with CC-486 in part 1 arm B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4eefdbd5b10a450837b99a92154c80bc
https://doi.org/10.1158/1078-0432.22469373
https://doi.org/10.1158/1078-0432.22469373
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Table S1. CC-486 Plus Carboplatin Dose Levels in Part 1 Arm A Table S2. CC-486 Plus nab-Paclitaxel Dose Levels in Part 1 Arm B Table S3. CC-486 Dose Levels in Part 1 Arm C Table S4. Number of Patients With Treatment Emergent Adverse Events for Part 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91814ef9e8949aae1e95bacbfce8808a
https://doi.org/10.1158/1078-0432.22469364
https://doi.org/10.1158/1078-0432.22469364
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Mean total carboplatin plasma concentration following carboplatin administration alone or with CC-486 in part 1 arm A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::682bf5cb413b4e7a057f3bc39464dbea
https://doi.org/10.1158/1078-0432.22469376
https://doi.org/10.1158/1078-0432.22469376
Autor:
Kent Shih, Jorge DiMartino, Kristen Hege, Rajesh Chopra, Xin Wei, Yan Li, Patrick R. Hagner, Anita K. Gandhi, Michael Pourdehnad, Kyriakos P. Papadopoulos, Drew W. Rasco
Supplementary Table S1. Summary of avadomide plasma pharmacokinetic parameters by day and dose level Supplementary Figure S1. Representative flow cytometry analysis of Aiolos degradation in peripheral B cells (A) and T cells (B). Supplementary Figure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d569f825271d3d9d426a19adb038cf8
https://doi.org/10.1158/1078-0432.22475361.v1
https://doi.org/10.1158/1078-0432.22475361.v1
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Pharmacodynamic Assessments
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc5a6bc2fae21e4f0b16b715a823c0ad
https://doi.org/10.1158/1078-0432.22469367.v1
https://doi.org/10.1158/1078-0432.22469367.v1
Autor:
Kent Shih, Jorge DiMartino, Kristen Hege, Rajesh Chopra, Xin Wei, Yan Li, Patrick R. Hagner, Anita K. Gandhi, Michael Pourdehnad, Kyriakos P. Papadopoulos, Drew W. Rasco
Purpose:Avadomide is a novel, small-molecule therapeutic agent that modulates cereblon E3 ligase activity and exhibits potent antitumor and immunomodulatory activities. This first-in-human phase I study (NCT01421524) evaluated the safety and clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3493b884ac4e44e927195fd863923738
https://doi.org/10.1158/1078-0432.c.6529056
https://doi.org/10.1158/1078-0432.c.6529056
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Correlation analysis between pharmacodynamic and pharmacokinetic findings in part 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50f70f4ed0a92b75190f034aea2886e5
https://doi.org/10.1158/1078-0432.22469370.v1
https://doi.org/10.1158/1078-0432.22469370.v1
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Purpose: This large two-part, three-arm phase I study examined the safety and tolerability of CC-486 (an oral formulation of azacitidine, a hypomethylating agent) alone or in combination with the cytotoxic agents, carboplatin or nab-paclitaxel, in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fe263d5c1a31e04f57ce2ef635de4d3
https://doi.org/10.1158/1078-0432.c.6527238.v1
https://doi.org/10.1158/1078-0432.c.6527238.v1
Autor:
Douglas C. Saffran, Melinda A.L. Day, Nathalie Rioux, Tom Chen, Christina Lee, Suha Naffar-Abu Amara, David B. Freeman, Tressa Hood, Charles Y. Lin, Pavan Kumar, Jorge DiMartino
Publikováno v:
Cancer Research. 82:P5-08
KB-0742 is an orally available, potent, and selective inhibitor of cyclin-dependent kinase 9 (CDK9). Sensitivity profiling across a panel of 800 adherent and suspension immortalized pan-cancer cell lines using the Broad Institute PRISM platform had p